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The overall aim of this article is to review current therapeutic strategies for treating AD, with a focus on mitochondrially tar-
geted antioxidant treatments. Recent advances in molecular, cellular, and animal model studies of AD have revealed that amyloid
precursor protein derivatives, including amyloid beta (Aβ) monomers and oligomers, are likely key factors in tau hyperphospho-
rylation, mitochondrial oxidative damage, inﬂammatory changes, and synaptic failure in the brain tissue of AD patients. Several
therapeutic strategies have been developed to treat AD, including anti-inﬂammatory, antioxidant, and antiamyloid approaches.
Among these, mitochondrial antioxidant therapy has been found to be the most eﬃcacious in reducing pathological changes and
in not producing adverse eﬀects; thus, mitochondrial antioxidant therapy is promising as a treatment for AD patients. However, a
major limitation in applying mitochondrial antioxidants to AD treatment has been the inability of researchers to enhance antiox-
idant levels in mitochondria. Recently, however, there has been a breakthrough. Researchers have recently been able to promote
the entry of certain antioxidants—including MitoQ, MitoVitE, MitoPBN, MitoPeroxidase, and amino acid and peptide-based
SS tetrapeptides—into mitochondria, several hundred-fold more than do natural antioxidants. Once in the mitochondria, they
rapidly neutralize free radicals and decrease mitochondrial toxicity. Thus, mitochondrially targeted antioxidants are promising
candidates for treating AD patients.
Copyright © 2006 P. Hemachandra Reddy. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Alzheimer’s disease (AD) is a complex, multifactorial, het-
erogeneous mental illness, which is characterized by an age-
dependent loss of memory and an impairment of multi-
ple cognitive functions. AD is associated with the presence
of intracellular neuroﬁbrillary tangles (NFTs) and extracel-
lular amyloid beta (Aβ) plaques, the loss of neuronal sub-
populations, mitochondrial oxidative damage, synaptic loss,
and the proliferation of reactive astrocytes and microglia [1].
With the life span of humans increasing and with decreas-
ing cognitive function in elderly individuals with AD-related
dementia, AD has become a major health problem in soci-
ety. Therapeutic interventions are urgently needed to mini-
mize the ill eﬀects of this devastating disease. Genetic mu-
tations are responsible for causing early onset “familial” AD
(constituting only 2% of AD cases), but the causal factor(s)
for the vast majority of late-onset “sporadic” AD cases is
still unknown. In addition, cellular changes in AD neurons
that occur in late-onset AD are also unknown. This article
describes cellular changes in AD progression and AD ther-
apeutic strategies, and then focuses on mitochondrially tar-
geted antioxidants as potential therapies for AD.
HISTOPATHOLOGICAL AND CELLULAR CHANGES IN
AD PROGRESSION
Histological, pathological, molecular, cellular, and gene ex-
pression studies of AD have revealed that multiple cellu-
lar pathways are involved in AD progression [2, 3]. Patho-
logically, there are no diﬀerences between early- and late-
onset AD [4]. In patients with late-onset AD, pathologi-
cal changes—including Aβ production and deposits, NFTs,
synaptic damage, and neuronal loss—occur later than in pa-
tientswithearly-onsetAD[1,4–6].Incontrasttoearly-onset
ADinwhichgeneticmutationsacceleratethediseaseprocess,
in late-onset AD, in the absence of genetic mutation, age-
related cellular changes control AD progression [6]. There-
fore, late-onset AD takes more time to develop [4]. Much2 Journal of Biomedicine and Biotechnology
research has been done on early-onset AD in terms of patho-
physiology and cellular changes that regulate AD progres-
sion, but we still need more research to understand causal
factors, pathophysiology, and cellular changes that are re-
sponsible for disease development and progression in late-
onset AD.
Several factors are known to be involved in the devel-
opment of late-onset AD, with two of the major ones be-
ing aging [1] and mitochondrial abnormalities [5–9]. Other
contributing factors are the ApoE genotype [10, 11], insulin-
dependent diabetes [12], and environmental conditions, in-
cluding diet [13].
Inearly-onsetAD,recentmolecular,cellular,andanimal-
model studies have provided evidence that a 4kd peptide, a
cleavage product of amyloid precursor proteins (APP) due to
cleavage of β and γ secretases, is a key factor in AD develop-
mentandprogression[4].Theformationofthe4kdAβ pep-
tide in the brains of AD patients is a progressive and sequen-
tial process. Initially, soluble monomeric and oligomeric
forms of 40–42 amino acid residues accumulate and later be-
come insoluble ﬁbrils and Aβ deposits. Recent cellular and
molecularstudiesoftripleADtransgenicmicesuggestedthat
Aβ production in early-onset AD may facilitate tau pathol-
ogy [14–16]. The Aβ plaques in the transgenic mice were
also found to be associated with activated microglia and as-
trocytes and to trigger inﬂammatory responses [17]. In ad-
dition, recent molecular, cellular, and animal model stud-
ies have revealed that mutant APP and Aβ enter mitochon-
dria and interact with an Aβ-induced alcohol dehydrogenase
(ABAD) protein, disrupt the electron transport chain (ETC),
generate reactive oxygen species (ROS), free radicals derived
from molecular oxygen in the mitochondria, and inhibit the
generation of cellular adenosine triphosphate [5, 6, 18, 19].
These results suggest that mutant APP and mutant Aβ in-
teracting with mitochondrial proteins cause mitochondrial
dysfunction in early-onset AD [5, 6, 18].
THERAPEUTIC STRATEGIES
Recent cellular and animal model studies revealed that AD
progression involves such cellular changes as inﬂammatory
responses, mitochondrial oxidative damage, synaptic failure,
andhyperphosphorylationoftau,allofwhicharedirectlyre-
lated to aging and Aβ production [13–16, 20–24]. Based on
cellular, histopathological, and behavioral changes observed
in postmortem brains of late-onset AD patients and in AD
transgenic mouse models, several therapeutic strategies have
been developed to treat AD patients, including immunother-
apy [15, 25–28], anti-inﬂammatory therapy [29–32], antiox-
idant therapy [33–43], cholinergic therapy [44–51], cell cy-
cle therapy [8, 52–54], and hormonal therapy [55–57]. This
article brieﬂy discusses four of these major therapeutic ap-
proaches, with special emphasis on mitochondrially targeted
antioxidants.
IMMUNOTHERAPY
Current immunotherapeutic strategies are aimed at decreas-
ing Aβ levels in late-onset AD patients by inhibiting Aβ
generation [58], reducing soluble Aβ levels [59, 60], and en-
hancing Aβ clearance from the brain [15, 26–28].
Immunization of Aβ in AD transgenic mouse models
has shown that Aβ levels can be reduced in the brains of
AD mice [14, 25–27]. With encouraging results from in vivo
studies that have aimed at abolishing Aβ deposits in cellu-
lar and animal models of AD, Elan Pharmaceuticals moved
quickly to investigate, in phase II clinical trials, immunother-
apy to reduce Aβ [25]. However, this research was stopped
because AD subjects developed symptoms of aseptic menin-
goencephalitis [25]. The following critical issues need to be
addressed before resuming immunotherapy clinical trials us-
ing AD subjects: (1) the long-term consequences of Aβ im-
munization for the AD brain need to be identiﬁed, (2) even
though immunotherapy has been found to clear Aβ deposits
in the AD brain, the downstream eﬀects of AD progression
still need to be determined, and (3) the relationship between
theclearingofAβandtheimprovementofcognitivefunction
in AD patients needs to be clariﬁed. Currently, several labo-
ratories are actively involved in immunotherapy research to
clear both soluble and insoluble Aβ from the brain and to
improve behavioral changes in AD transgenic mice.
ANTI-INFLAMMATORY THERAPY
Inﬂammation of brain tissue is an important component in
the pathogenesis of AD, involving the activation of both mi-
croglia and astrocytes. Recent histological studies have re-
vealed the presence of activated microglia and reactive as-
trocytes in and around extraneuronal Aβ plaques in brains
from AD patients. These activated microglia and reactive as-
trocytes are believed to facilitate the clearing of Aβ deposits
from the brain parenchyma [13]. However, now there is in-
creasing evidence to suggest that the chronic activation of
microglia, presumably via the secretion of cytokines and re-
active molecules [61, 62], may exacerbate Aβ plaque pathol-
ogy as well as enhance the hyperphosphorylation of tau and
the formation of NFTs [14–16]. Thus, the suppression of mi-
croglial activity in the AD brain has been considered a pos-
sible therapeutic strategy to treat AD patients [13, 30]. Sup-
pressive anti-inﬂammatory drugs, particularly nonsteroidal
anti-inﬂammatory drugs, have been found to lessen the ef-
fects of Aβ in transgenic mice [29–32].
CHOLINERGIC THERAPY
AD aﬀects cholinergic neurotransmission in the neurons of
the basal forebrain [63]. There is increasing evidence that
the enzymes involved in the synthesis of choline acetyltrans-
ferase (ChAT) and the degradation of acetylcholine (ACh)
may be responsible for deﬁcits in cholinergic neurotransmis-
sion. Strategies to boost the levels of ACh in the AD brain
are being developed to treat AD patients, to reduce NFTs
and Aβ levels, and to improve cognition. Similar to ChAT,
butylcholinesterase (BChE) inactivates the neurotransmit-
ter ACh and, thus, is a viable therapeutic target for AD.
Greig et al [47] tested potent, reversible, and brain-targeted
BChE inhibitors (cymserine analogs). In rats, cymserineP. Hemachandra Reddy 3
analogs caused long-term inhibition of brain BChE and ele-
vated extracellular ACh levels, without inhibiting ChAT [47].
In slices from rat brains, selective BChE inhibition aug-
mented long-term potentiation. These compounds (cym-
serine analogs) improved the cognitive performance (maze
navigation) of aged rats. In cultured human SK-N-SH neu-
roblastoma (N2a) cells, BChE inhibitors reduced intra- and
extracellular Aβ precursor proteins and secreted Aβ pep-
tides without aﬀecting cell viability. Cholinergic treatment of
transgenic mice overexpressing human mutant APP also re-
sulted in lower levels of Aβ peptides in their brains than the
levelsofAβpeptidesinthebrainsfromhealthy(control)rats.
Selective, reversible inhibition of brain BChE may be a viable
treatmentforADtoimprovecognitionandtomodulateneu-
ropathological markers of the disease. Discoveries in cholin-
ergictherapeuticshavealreadyledtothedevelopmentofsev-
eral cholinesterase inhibitors [44–51]. Four cholinesterase-
inhibiting drugs are currently being prescribed for patients
with mild to moderate AD: Donepezil, Rivastigmine, Galan-
tamine,andTacrine.However,thesedrugsprovideonlytem-
porary relief of AD symptoms, and there is no evidence as
yet to suggest that they reduce AD pathology. As a result,
cholinergic therapy is considered a short-term intervention
forcertainsymptomsofAD,sinceitisstillunknownwhether
cholinesterase inhibitors modify Aβ pathology in AD mouse
modelsandinADpatients.Thisissuehasbeenunderintense
investigation in many laboratories across the world.
OXIDATIVE STRESS AND ANTIOXIDANT THERAPY
Oxidative stress is a major factor associated with the devel-
opment and progression of AD and other forms of demen-
tia. A large body of data suggests that free radical oxida-
tivedamage—particularlyofneuronallipids[64,65],nucleic
acids [23, 24, 66–68], and proteins [66, 67, 69, 70]—is exten-
sive in the brains of AD patients. Increased oxidative stress is
thought to result in the generation of free radicals and ROS,
which is reported to be released by microglia activated by Aβ
[71,72].Comparedtootherorgans,thebrainhasbeenfound
to be more vulnerable to oxidative stress due to its high lipid
content, its relatively high oxygen metabolism, and its low
level of antioxidant defenses [70, 73, 74]. Markers of oxida-
tive stress, such as 8-hydroxyguanosine and hemeoxygenase,
have been localized to pathologic lesions in the brains of AD
patients [75–78].
Using PC 12 cells and Aβ (25–35) peptide, Bozner et
al studied the connection between Aβ and mitochondrial
DNA damage. They exposed PC 12 cells to an Aβ (25–35) in
frameandscrambledat50mMconcentrationfor24hoursto
50 hours. Oxidative damage of mitochondrial DNA was as-
sessed using a Southern blot technique and a mitochondrial
DNA-speciﬁc probe recognizing a 13.5-kilobase restriction
fragment. PC 12 cells exposed to Aβ e x h i b i t e dm a r k e do x -
idative damage of mitochondrial DNA as evidenced by char-
acteristic changes on Southern blots, but not in cells exposed
to the scrambled Aβ peptide, suggesting that Aβ peptide is
responsible for mitochondrial DNA damage, and ultimately
leading to mitochondrial dysfunction in AD [68]. Further,
evidence from a recent gene expression study [21] suggests
that mutant APP or Aβ may generate free radicals and pro-
mote mitochondrial dysfunction, one or both of which may
lead to oxidative damage. Altered levels of mitochondrial en-
zymes have been found to be directly responsible for a de-
crease in energy production in the brains of late-stage AD
patients [5]. Soluble or insoluble forms of Aβ have been sug-
gested to impair ATP production by generating defects in
mitochondrial energy metabolism and oxidative stress [79].
Taken together, these results suggest that oxidative stress is a
key event in AD pathogenesis.
FREE RADICAL PRODUCTION AND MITOCHONDRIAL
OXIDATIVE DAMAGE
In the literature on AD, the terms “oxidative stress” or “ox-
idative damage” are commonly used to explain the balance
between the production of oxidants and the endogenous an-
tioxidant defenses in neuronal cells. In general, cells undergo
apoptoticdeathwhenthereisanimbalancebetweenoxidants
and antioxidants (more oxidants than antioxidant defenses).
This oxidative damage mainly occurs via the mitochondrial
ETC [5, 6].
Mitochondria, which are cytoplasmic organelles, are re-
sponsible for the production of cellular ATP. Mitochondria
areinvolvedin3importantcellfunctions:(1)producingATP
and regulating intracellular Ca2+; (2) releasing proteins that
activate the caspase family of proteases; and (3) altering the
reduction-oxidation potential of cells [5]. Disruption of the
ETC has been recognized as an early characteristic of apop-
totic cell death. ETC involves the reduction of hydrogen per-
oxide (H2O2)t oH 2Oa n dO 2 by catalase or glutathione per-
oxidase accepting electrons donated by NADH and FADH2,
and then yielding energy for the generation of ATP from
adenosine diphosphate and inorganic phosphate [6, 80–82].
The production of mitochondrial superoxide radicals
(O
•−
2 ) occurs primarily at discrete points in the ETC at com-
plexes 1 and 3 [83], and in components of tricarboxylic
acid (TCA), including α-ketoglutarate dehydrogenase [84]
(see Figure 1). In addition, mitochondrial O
•−
2 are gener-
ated in the outer mitochondrial membrane. Monoamine ox-
idase (ﬂavoprotein), localized on the outer mitochondrial
membrane, catalyzes the oxidative deamination of primary
aromatic amines. This deamination is a quantitatively large
source of H2O2 that contributes to an increase in the steady-
state concentrations of ROS within both the mitochondrial
matrix and the cytosol [80]. These released H2O2 and O
•−
2
are carried to the cytoplasm via voltage-dependent anion
channels and, ultimately, lead to the oxidation of cytoplas-
mic proteins (see Figure 1). The chronic exposure of ROS to
cellscanresultinoxidativedamagetomitochondrialandcel-
lular proteins, lipids, and nucleic acids, and acute exposure
to ROS can inactivate the TCA-cycle aconitase and the iron-
sulfur centers of ETC at complexes 1, 2, and 3, resulting in a
shutdown of mitochondrial energy production [5, 6, 85].
The generation of free radicals can occur via several cel-
lular insults, including ultraviolet irradiation [86], redox-
cyclingofquinones[86],themetabolismofxenobiotics[86],4 Journal of Biomedicine and Biotechnology
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Figure 1: Illustration of sites of free radical generation in the mitochondria. In the respiratory chain, complexes 1 and 3 leak electrons to
oxygen, producing primarily superoxide radicals (or O
•−
2 ). The O
•−
2 are dismutated by manganese superoxide dismutase to generate H2O2
andoxygen.Complex1generatesO
•−
2 onlytowardthematrix.Complex3,ontheotherhand,generatesO
•−
2 towardboththeintermembrane
space and the matrix. The components of tricarboxylic acid, including α-ketoglutarate dehydrogenase, also generate O
•−
2 in the matrix. Free
radicals are generated in the outer mitochondrial membrane (monoamine oxidase) and catalyze the oxidative deamination of primary
aromatic amines, leading to the generation of H2O2.
aging [87], environmental mitochondrial toxins [88–90],
and mutant toxic proteins (eg, Aβ in AD, mutant hunt-
ingtin in Huntington’s disease, alpha-synuclein in Parkin-
son’s disease, mutant SOD1 in amyotrophic lateral sclerosis)
[5, 8, 87].
FREE RADICALS, ABNORMAL PROCESSING OF APP,
AND Aβ METABOLISM
There is mounting evidence to suggest that in late-onset AD,
age-related free radicals, which are generated in the mito-
chondria, are carried to the cytoplasm where they activate
beta secretase and facilitate the cleavage of the APP molecule
[6]. The cleaved APP molecule (ie, Aβ) further generates free
radicals, leading to the disruption of the ETC and enzyme
activities, the inhibition of ATP, and the subsequent oxida-
tion of both nuclear and mitochondrial DNA proteins. The
damagecausedbymitochondriaultimatelyleadstoneuronal
damage, neurodegeneration, and cognitive decline in AD pa-
tients [6].
AGE-DEPENDENT MITOCHONDRIAL Ca2+ AND
OXIDATIVE DAMAGE
The dysregulation of age-related Ca2+ and an increased pro-
duction of ROS may contribute to late-onset neurodegener-
ative disorders such as AD. These alterations are often at-
tributed to impaired mitochondrial function, yet few stud-
ies have directly examined isolated mitochondria from var-
ious regions of the aged brain. Recently, Brown et al [91]
examined Ca2+ inﬂux and ROS production in isolated mi-
tochondria from Fischer 344 rats ranging in age from 4 to
25 months. Isolated mitochondria from the cortex of the 25-
month-old rat brain exhibited greater rates of ROS produc-
tion and mitochondrial swelling in response to increasing
Ca2+ loads compared to mitochondria isolated from younger
(4- and 13-month-old) rats. This increased swelling is in-
dicativeoftheopeningofamitochondrialpermeabilitytran-
sition pore, suggesting an impaired Ca2+ inﬂux in aged ani-
mals (see Figure 1). These age-related diﬀerences were not
observed in isolated mitochondria from the cerebellum of
theserats.Together,theseresultssuggestregion-speciﬁc,age-
related alterations in mitochondrial responses to Ca2+ [91].
In addition to aging, in age-related diseases such as AD,
Aβ promotes the opening of the mitochondrial permeabil-
ity transition pore, through which free cytosolic Ca2+ en-
ter the mitochondria (see Figure 1). The mitochondrial Ca2+
may disrupt the ETC, which would elevate the production
of free radicals in the mitochondria [92]. To determine the
extent of free radical production and oxidative damage in
the spinal cord and neocortex of the rat brain, Sullivan et
al [93] studied several parameters of mitochondrial physiol-
ogy in the normal neocortex and spinal cord. In situ mea-
surements revealed signiﬁcantly higher levels of O
•−
2 pro-
duction, lipid peroxidation, and mitochondrial DNA oxida-
tion in the spinal cord than these levels in neocortical neu-
rons.Real-timePCRanalysisofmitochondrialgenesdemon-
strated diﬀerences in mitochondrial transcripts coupled with
decreases in complex 1 enzyme activity and in respiration,
in the spinal cord mitochondria. The threshold for calcium-
induced mitochondrial permeability transition was substan-
tially reduced in the spinal cord relative to the neocortex and
was modulated by lipid peroxidation. These ﬁndings suggest
that studying mitochondrial damage in the spinal cord mayP. Hemachandra Reddy 5
be productive in learning about causes of age-related neu-
rodegenerative diseases [93].
Aβ AND MITOCHONDRIAL FUNCTIONAL ASSOCIATION
To determine whether mitochondria are critical for cellular
toxicity induced by Aβ, Cardoso et al [94] investigated the
eﬀects of Aβ peptides in NT2 cells with mitochondria (NT2
-P+) and without mitochondria (NT2 -P0) [94]. In NT2 -
P+ cells, they observed a decrease in cell viability, mitochon-
drial membrane potential, enzyme activities, and ATP levels,
but they did not ﬁnd such decreases in NT2 -P0 cells, sug-
gesting that Aβ peptides require functional mitochondria for
theinductionofcelltoxicity.Further,severalstudiesreported
the association of mutant APP derivatives with mitochon-
dria [18, 19, 95]. Anandatheerthavarada et al [95]o b s e r v e d
that in cortical neurons, the accumulation of full-length APP
in the mitochondrial compartment in a transmembrane-
arrested form of APP is responsible for mitochondrial dys-
function and impaired energy metabolism [95]. Lustbader et
al [18] demonstrated that Aβ is localized to mitochondria in
the neurons of AD transgenic mice. Further, they also found
that Aβ directly interacts with an Aβ-binding ABAD pro-
tein in the mitochondria, leading to oxidative damage and
mitochondrial dysfunction [18]. Crouch et al [19] studied
the inhibitory potential of synthetic Aβ (1–42) on the activ-
ity of ETC enzyme complexes in human mitochondria. They
foundthatsyntheticAβ(1–42)inhibitstheterminalcomplex
cytochrome c oxidase in a manner that is dependent on the
presence of Cu2+. In the Crouch study, maximal cytochrome
coxidaseinhibitionoccurredwhensyntheticAβ(1–42)solu-
tionswereusedaftertheyagedfrom3to6hoursat30◦C.The
levelofAβ (1–42)-mediated cytochromec oxidase inhibition
increased up to 6 hours after the Aβ (1–42) solution aged,
and then the level declined progressively as the Aβ (1–42)
solutions aged to 48 hours. These data strongly suggest that
endogenous Aβ is associated with brain mitochondria and
that synthetic Aβ (1–42) is a potent inhibitor of cytochrome
c oxidase [19]. All of these studies combine to suggest that
mitochondria are vulnerable to Aβ and/or age-related oxida-
tive damage.
ANTIOXIDANT TREATMENT
Using a Tg2576 mouse model of AD and treating the Tg2576
mice with a vitamin E-supplemented diet, researchers in in
vivo studies reported decreased Aβ (1–40) and Aβ (1–42)
levels [34, 35]. In another study, researchers using a trans-
genic mouse model of tau pathology found that the adminis-
trationofvitaminEamelioratedtauaggregates[33],suggest-
ing that vitamin E may have a direct eﬀect on AD pathology
[34,35].Theadministrationofcurcumin(anantioxidant)to
Tg2576 mice also showed encouraging results when both ox-
idative damage and Aβ deposits were reduced [38]. Further,
melatonin reduced brain levels of Aβ and abnormal protein
nitration, and increased the life span of Tg2576 mice [36].
A synthetic superoxide (a dismutase catalase mimetic) pre-
vented cataracts in AD transgenic mice [96].
Several recent antioxidant studies using AD patients re-
vealedbeneﬁcialeﬀectsofdietssupplementedwithvitaminE
[39, 40, 42]. The combined administration of vitamin E and
vitamin C supplements was associated with a reduced preva-
lence and incidence of AD in an elderly population [43].
Morris et al [41] examined whether food intake of vitamin
E, alpha-tocopherol equivalents (a measure of the relative bi-
ologic activity of tocopherols and tocotrienols), or individ-
ual tocopherols protects against AD symptoms and cogni-
tive decline. They found that higher intake of vitamin E and
alpha-tocopherol equivalents was associated with a reduced
incidence of AD in an elderly population, suggesting that an-
tioxidant treatment at the early onset of disease may be ef-
fective in delaying AD progression [41]. However, the patho-
logical eﬀects of oxidative stress are yet to be assessed in AD
patients or elderly individuals treated with antioxidants. In
another clinical study, to determine the neuroprotective ef-
fects of cholinesterase inhibition and oxidative stress in AD
patients, huperzine A (an antioxidant) was administered to
AD patients in doses of 300mg/d for the ﬁrst 2–3 weeks of
drug administration and then 400mg/d for the next 4–12
weeks. At the end of 12 weeks, the AD patients exhibited sig-
niﬁcant improvement in their cognitive, noncognitive, and
ADL functions [97]. These initial clinical trials may eventu-
ally become precursors for antioxidant clinical trials for AD
patients.
MITOCHONDRIALLY TARGETED ANTIOXIDANT
THERAPIES IN AGING AND AD
Krzepilko et al [98] studied exogenous mitochondrial an-
tioxidants in yeast (Saccharomyces cerevisiae) mutants. They
found that yeast mutants lacking CuZn-superoxide dismu-
tase are hypersensitive to oxygen and have a signiﬁcantly
decreased replicative life span [98]. These defects can be
ameliorated by the low-molecular weight exogenous antioxi-
dant ascorbate. The eﬀect of ascorbate on life span is com-
plicated by its auto-oxidation in yeast cell culture media.
Krzepilko and colleagues found that if negative eﬀects of
auto-oxidation are prevented by exchange of the medium,
ascorbate prolongs not only the mean but also the maximal
replicative life span of the yeast in an atmosphere of air and
pure oxygen. The ﬁndings from this study suggest that the
shortening of a healthy life span due to the lack of an antiox-
idant enzyme may be ameliorated by ascorbate [98].
In studies of the transgenic fruit ﬂy Drosophila that over-
expresses antioxidant enzymes targeted to mitochondria,
Ruanetal[99] found that the antioxidant enzymes Mn-SOD
(manganesesuperoxide dismutase) and methionine sulfox-
ide reductase extended the life span of Drosophila, suggest-
ing that mitochondrially targeted antioxidants may reduce
ROS and contribute to life span extension [99]. However, re-
cently, Magwere et al [100] tested the eﬀects of SOD mimetic
drugs Euk-8 and -134, and the mitochondrially targeted mi-
toquinone (MitoQ) on life span and oxidative stress resis-
tance of wild-type and SOD-deﬁcient ﬂies. They conﬁrmed
ﬁndings from other researchers that exogenous antioxidants
rescue pathology associated with compromised deﬁciencies6 Journal of Biomedicine and Biotechnology
to oxidative stress, but do not extend the life span of normal,
wild-type ﬂies treated with exogenous antioxidants. All three
exogenous antioxidants (Mn-SOD, MitoQ, and Euk-8 and
-134) led to a dose-dependent increase in toxicity in wild-
typeﬂies,aneﬀectthatwasexacerbatedinthepresenceofthe
redox-cycling drug, paraquat. However, important ﬁndings
from this study were that in SOD-deﬁcient ﬂies, the antiox-
idant drugs increased life span. Further, the eﬀects of these
antioxidant drugs were sex-speciﬁc, and for either sex, the
eﬀects were also variable depending on (1) the stage of de-
velopment at which the drugs were given, and (2) the mag-
nitude of the dose [100].
Schriner et al [101] recently demonstrated that mito-
chondrially targeted catalase decreases H2O2,l e a d st or e -
ducedmitochondrialoxidativedamage,andincreasesthelife
span of catalase transgenic mice. To determine the role of
catalase in mitochondrial function, they created mouse lines
that overexpress human catalase localized to peroxisomes,
nuclei, and mitochondria, to elucidate the eﬀects of cata-
lase on aging from birth to death. Catalase, found mainly
in peroxisomes, rapidly converts toxic H2O2 into H2Oa n d
O2 [6]. In two independent lines of mitochondrial catalase
(MCAT) mice, Schriner et al [101] found that the trans-
genic mice treated with MCAT expressers showed about a
20% increase in median and maximal life span (on aver-
age, 5.5 months) compared to the life span of nontrans-
genic, age-matched wild-type littermates. The ability of cata-
lase to increase longevity was most apparent when the en-
zyme was targeted to mitochondria. Schriner et al found that
the transgenic mice, which express catalase in peroxisome,
had a slightly longer median life span, but showed no in-
crease in maximal life. Nuclear catalase (NCAT) expression
(in NCAT mice) had no eﬀect on either the median life span
or the maximal life span of the mice [101].
In the Schriner study [101], MCAT transgenic mice ap-
peared to age more slowly than their age-matched litter-
mates by several measures. While histological comparisons
showed little diﬀerence between wild-type and MCAT lines
in young mice (9 to 11 months old), aged transgenic mice
(20 to 25 months old) had signiﬁcantly less arteriosclerosis
and cardiomyopathy than their wild-type littermates. Bio-
chemical studies have shown that the slower aging found in
the MCAT mice is associated with a lower level of oxidative
stress and DNA damage [101]. In the Schriner study [101],
H2O2 productionbycardiacmitochondriafromMCATmice
decreased 25%, and mitochondria containing catalase were
protected from the toxic eﬀects of H2O2. Age-related in-
creases in oxidative damage to total DNA and fragmentation
of mitochondrial DNA were also slowed in the skeletal mus-
cle of MCAT mice [101].
Overall, ﬁndings from these aging studies suggest that
mitochondrially targeted antioxidants reduce ROS produc-
tion and oxidative damage in that the ﬂies were diseased
and also contribute to healthy aging at least in laboratory
mice. However, the eﬀects of mitochondrial antioxidants in
healthy humans and humans with neurodegenerative disease
still need to be determined.
From these aging studies, it is clear that mitochondrially
generated H2O2 is a critical factor in determining life span.
If aging is a key to the generation of H2O2 in aged neurons,
then mitochondrially targeted catalase, glutathione peroxi-
dase,MitoQ[102],MitoVitE[103],MitoPBN[104],andsev-
eral mitochondrially targeted peptides [105, 106] may likely,
rapidly convert toxic H2O2 into H2Oa n dO 2. This continu-
ous conversion of H2O2 into H2Oa n dO 2 may reduce oxida-
tive damage in aged neurons and may maintain mitochon-
drial function in the neurons of aged individuals. It has been
established that an overload of Ca2+ induces ROS and dis-
rupts the ETC in mitochondria. It is also possible that mi-
tochondrially targeted antioxidants reduce ROS induced by
an age-related overload of Ca2+ in mitochondria [91, 92].
Since age is a major factor involved in the development of
late-onset AD, mitochondrially targeted antioxidants may be
able to reduce oxidative damage in AD, increase O2 con-
sumption, help increase the life span of elderly individuals,
and decrease or prevent AD progression in elderly individu-
als [6].
A major limitation in using antioxidant therapy to
treat the age-related diseases, such as AD, has been the
inability of investigators to enhance the antioxidant lev-
els in mitochondria [107]. However, in the last 5 years,
considerable progress has been made in developing mi-
tochondrially targeted antioxidants. To increase the deliv-
ery of antioxidants to mitochondria, three types of an-
tioxidants are being studied: triphenylphosphonium-based
antioxidants, and amino acid- and peptide-based antioxi-
dants.
HOW DO MITOCHONDRIALLY TARGETED
ANTIOXIDANTS ENTER MITOCHONDRIA?
The mitochondrial ETC participates in the transfer of elec-
trons to O2 [6]. During this transfer, a proton gradient is
generated, which drives the production of ATP by ATP-
synthase [86] .A T Pp r o d u c t i o ni nt u r ng e n e r a t e san e g a t i v e
potential from 150 to 180mV across the inner mitochon-
drial membrane. This negative potential gradient is used to
deliver liphophilic cations to mitochondria. The liphophilic
cations easily permeate through the lipid bilayers and subse-
quently accumulate by several hundred-fold within the mi-
tochondria, given their large mitochondrial membrane po-
tential (see Figure 2). Using this known transfer of elec-
trons to O2, Murphy and colleagues recently developed sev-
eral mitochondrially targeted antioxidants: MitoQ (a deriva-
tive of mitochondrial quinoline), MitoVitE (a derivative of
mitochondrially targeted vitamin E) [102, 107], and Mi-
toPBN (a derivative of α-phenyl-N-tert-butyl nitrone) [104].
These liphophilic cations-based antioxidants were covalently
coupled to a triphenylphosphonium cation and were pref-
erentially taken up by mitochondria [102–104]. These an-
tioxidants initially accumulated in the cytoplasm of cells,
due to a negative plasma membrane potential (see Figure 2)
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5–10times
100–500times Matrix
Plasma membrane potential
(−30 to −60mV)
Mitochondrial membrane potential
(−150 to −180mV)
Mitochondrion
Nucleus
Mitochondrially targeted antioxidants
A : Mitochondrially targeted antioxidant
LTC: Lipophilic triphenylphosphonium cation
Figure 2: Illustration of mitochondrially targeted antioxidants. A generic mitochondria-targeted antioxidant is shown constructed by the
covalent attachment of an antioxidant molecule to the lipophilic triphenylphosphonium cation. Antioxidant molecules accumulate 5- to
10-fold in the cytoplasm, which is driven by the plasma membrane potential, and then further accumulate several hundred-fold in the
mitochondria.
MitoQ
MitoQisanantioxidantconsistingoftworedoxformsofmi-
tochondrially targeted ubiquinone derivatives: reduced mi-
toquinolandoxidized mitoquinone[102].MitoQisattached
to a phosphonium cation [10-(6-ubiquinonyl) decyltriph-
enylphosphonium bromide]. The molecular formula of Mi-
toQ is C37H46O4PBr, and its molecular weight is 665.65. Mi-
toQisared,oilysolidandcanbestoredat −20◦Cinthedark.
It can be converted into a fully oxidized form by incubation
in 95% ethanol and can be dissolved in DMSO.
MitoQ is a promising therapeutic antioxidant that has
been successfully targeted to mitochondria [102]. MitoQ is
a respiratory chain component buried within the lipid core
of the inner membrane of mitochondria where it accepts 2
electronsfromcomplex1or2,toformthereductionproduct
ubiquinol, which donates electrons to complex 3 [109]. The
ubiquinone pool in vivo exists largely in a reduced ubiquinol
form,actingasanantioxidantandamobileelectrontransfer.
Ubiquinolhasbeenreportedtofunctionasanantioxidantby
donating a hydrogen atom from one of its hydroxyl groups
to a lipid peroxyl radical, thereby decreasing lipid peroxida-
tion within the mitochondrial inner membrane [110–112].
The semiubiquinone radical formed during this process dis-
proportionates into ubiquinone and ubiquinol [113]. The
respiratory chain subsequently recycles ubiquinone back to
ubiquinol, restoring its antioxidant function. MitoQ exces-
sively accumulates in the mitochondria and converts H2O2
toH2OandO 2,andreducestoxicinsultsfromfreeradicalsin
themitochondria.Thisreductionultimatelyleadstothepro-
tection of neurons from age-related and/or disease-related
mitochondrial insults in AD.
Recently, the eﬀects of MitoQ on mitochondria in sev-
eral in vitro cell models were tested [114–117]. In cultured
ﬁbroblasts from Friedreich Ataxia patients, MitoQ prevented
celldeathknowntobecausedbyendogenousoxidativestress
[115]. In a study of PC12 cells, low concentrations of Mi-
toQ (1μM) selectively inhibited serum deprivation-induced
apoptosis in PC12 cells [116]. In a study of bovine aortic en-
dothelial cells treated with glucose/glucose oxidase and lipid
peroxide, MitoQ inhibited cytochrome c release, caspase 3
activation, and DNA fragmentation in greater percentages
than did the corresponding untargeted counterparts such as
vitamin E [117]. These studies suggest that MitoQ may re-
duce free radicals, decrease oxidative damage, and maintain
mitochondrial function. Since oxidative damage is part of
the known pathophysiology of AD, there is strong interest in
determining whether mitochondrially targeted antioxidants
decrease oxidative damage in the neurons of AD patients [6].
Smith et al [118] studied the eﬀects of mitochondrially
targeted antioxidants, including MitoQ, on laboratory mice.
Some of the mice were fed with MitoQ for several weeks un-
til MitoQ reached steady-state concentrations within all tis-
sues assessed, including brain, heart, liver, and kidney tissues
[118]. At that point, the concentration of MitoQ in the tis-
sues was several hundred-fold higher than that in the blood-
stream. Smith et al [118] found the uptake of MitoQ to be
reversible, as observed by the rapid clearance of the simple8 Journal of Biomedicine and Biotechnology
lipophilic cation methyltriphenylphosphonium from all or-
gans when oral administration of MitoVitE was stopped. Us-
ing mass spectrometry, they found that orally administered
MitoQ entered the bloodstream and distributed in an intact
active form to tissues in the brain, heart, and liver. After the
mice were fed with methyltriphenylphosphonium and Mi-
toVitE, the levels of these accumulated antioxidants were in
the range of 5 to 20nmol/g (wet weight), or about 5 to 20
μmol/l in the tissues [118]. These high concentrations may
be in a therapeutic range since MitoQ has been found to pre-
ventoxidativedamageinisolatedmitochondriaatlowercon-
centrations (eg, 1 to 2.5 μmol/l [102, 103]). Therefore, the
oraladministrationofwell-tolerateddosesofMitoQmayde-
liver potentially therapeutic concentrations to mitochondria
in vivo [118].
Further, Adlam et al [119] recently examined the eﬀect
of MitoQ in a murine model of cardiac ischemia-reperfusion
injury(amitochondrialoxidativedamagemodel).MitoQfed
to rats signiﬁcantly decreased their heart dysfunction and
mitochondrial damage after ischemia reperfusion. This pro-
tection was attributed to MitoQ in the mitochondria [119].
Since natural antioxidants given at high doses without
side eﬀects have been shown to decrease oxidative damage in
AD mouse models and AD patients [33–43], there is a strong
rationale for testing these mitochondrially targeted antioxi-
dants in trials using AD cell and mouse models, and AD pa-
tients.
MitoVitE
MitoVitE is an antioxidant that consists of [2-3,4dihydro-
6-hydroxy-2,5,7,8tetra-methyl-2H-1-benzopyran-2-yl] and
triphenylphosphonium bromide [86]. MitoVitE is a deriva-
tive of vitamin E that is targeted to mitochondria, and it
wasdevelopedtostudymitochondrialoxidativedamage.Mi-
toVitE is rapidly taken up by mitochondria, and the uptake
lasts for 15min. Accumulation ratios of 5000–6000 unit have
been achieved after incubating mitochondria with 1–20μM
MitoVitE [86]. MitoVitE is cytotoxic at 50μM. The eﬀects
of MitoVitE have been tested in Jurkat cells. MitoVitE was
foundtoreduceH2O2-inducedcaspaseactivity[120];topre-
vent oxidative stress-induced cell death in cultured ﬁbrob-
lasts from Friederich Ataxia patients [115]; and at (1μM)
concentration, to inhibit cytochrome c release and caspase-3
activation, to inactivate complex 1, and to restore mitochon-
drialmembranepotentialandproteosomalactivityinbovine
aortic epithelial cells [117].
MitoPBN
MitoPBN is an antioxidant consisting of [4-[4 (1,1-dimeth-
ylethyl) oxidoimino]-methyl]phenoxy]butyl] and triphenyl-
phosphonium bromide [104, 121]. A mitochondrially tar-
geted analog of MitoPBN was prepared to determine the
eﬀect of ROS and mitochondrial function in mitochon-
dria, based on a selective PBN (α-phenyl-N-tert-butyl ni-
trone) reaction with carbon-centered radicals [104]. Similar
to MitoQ and MitoVitE, MitoPBN was rapidly taken up by
mitochondria, with a resulting concentration ranging from
2.2 to 4.0mM. It has been reported that MitoPBN blocks the
O-induced activation of uncoupled proteins.
Recently, Poeggeler et al [122] developed an amphiphilic
molecule, N-[4-(octa-O-acetyllactobionamidomethylene)
benzylidene]-N-[1,1-dimethyl-2-(N-octanoyl) amido]-eth-
ylamine N-oxide, (LPBNAH, a derivative of α-phenyl-N-
tert-butyl nitrone) that exhibits profound antioxidant and
neuroprotective activity and very eﬃciently antagonizes
oxidotoxicity of primarily mitochondrial origin [122].
LPBNAH, when administered via food to rotifers, was found
to decrease free radicals, to greatly enhance the survival
of neurons, and to increase the life span of rotifers. The
antiaging activity of LPBNAH exceeded that of other nitrone
compounds, such as the parent compound PBN, by at
least one order of magnitude. The development of such
a neuroprotective antioxidant may lead to more safe and
eﬀective treatments of age-related diseases such as AD.
AMINO ACID- AND PEPTIDE-BASED
MITOCHONDRIALLY TARGETED ANTIOXIDANTS
SS tetrapeptides are aromatic cationic peptides that con-
tain the structural motif of alternating aromatic and basic
amino acid residues, along with a 2 ,6  -dimethyltyrosine
residue [86]. These tetrapeptides are mitochondrially tar-
geted antioxidants. Their antioxidant properties are derived
from the related compound 3, 5-dimethyphenolis, a known
phenolic antioxidant [123]. SS tetrapeptides were originally
We prepared to develop centrally acting opiopoid analgesics
[124, 125]. The following SS tetreapeptide compounds have
been developed for mitochondrial and cellular uptake stud-
ies: (1) Dmt-D-arg-Phe-Lys NH2 (SS-02); (2) Phe-D-Arg-
Phe-Lys-NH2 (SS-20); (3) D-Arg-Dmt-Lys-Phe-NH2 (SS-
31); and (4) Dmt-d-Arg-Phe-atnDAP-NH2 (SS-19) [86].
SS-02 neutralizes H2O2 and inhibits the oxidation of
linoleic acid and low-density lipoproteins. SS-31 contains
same amino acid residues, as does SS-02, but in an order that
exhibits antioxidant properties. SS-02 is taken up by Caco-2
cells (derived from human colorectal adenocarcinoma), and
its intracellular concentration is about 10 times greater than
its extracellular concentration. SS-02 and SS-19 are rapidly
taken up by isolated mitochondria from mouse liver, with
accumulation in the mitochondria 105-fold. The incubation
of mitochondria with FCCP reduced the uptake of SS-19
by 20%, suggesting partial potential-dependent uptake [86].
Treatment of SS-02 with digitonin showed that about 85%
of SS-02 is present in the mitoplast (inner membrane plus
matrix).
Recently, Zhao et al [106] developed peptide antioxi-
dants that target the inner mitochondrial membrane. These
antioxidants were used to investigate the role of ROS and
the mitochondrial permeable transition of 3NP in cell death
caused by the peptides [t-butylhydroperoxide (tBHP) and 3-
nitropropionic acid (3NP)]. The structural motif of tBHP
and 3NP centers on alternating aromatic and basic amino
acid residues, with dimethyltyrosine providing scavenging
properties. BHP and 3NP were found to be cell-permeableP. Hemachandra Reddy 9
and to concentrate at 1000-fold in the inner mitochondrial
membrane. Peptide antioxidants potently reduced intracel-
lular ROS and cell death caused by tBHP in neuronal N2a
cells. These peptide antioxidants also decreased mitochon-
drial ROS production, inhibited mitochondrial permeability
transition and swelling, and prevented cytochrome c release
induced by Ca2+ in isolated mitochondria. In addition, pep-
tide antioxidants inhibited 3NP-induced mitochondrial per-
meability transition in isolated mitochondria and prevented
mitochondrial depolarization in cells treated with 3NP. ROS
and mitochondrial permeability transition have been im-
plicated in myocardial stunning associated with reperfusion
in ischemic hearts. Peptide antioxidants were found to po-
tently improve contractile force in an ex vivo heart model.
It is noteworthy that peptide analogs without dimethylty-
rosine did not inhibit mitochondrial ROS generation or
swelling, and did not prevent myocardial stunning. These re-
sults clearly suggest that ROS underlies the cellular toxicity
of tBHP and 3NP, and that ROS may mediate cytochrome c
release via a mitochondrial permeability transition. Peptide
antioxidants may be very beneﬁcial in the treatment of aging
and diseases associated with oxidative stress [106].
Further, Zhao et al examined the ability of a novel, cell-
penetrating, mitochondrially targeted peptide antioxidant to
protect against oxidant-induced mitochondrial dysfunction
and apoptosis in two neuronal cell lines [105]. Treatment
of neuronal cell lines with tBHP for 24 hours resulted in
lipidperoxidation,signiﬁcantcelldeathviaapoptosisinboth
N2a and SH-SY5Y cells, phosphatidylserine translocation,
nuclear condensation, and increased caspase activity. When
treated with tBHP, the N2a and SH-SY5Y cells showed a
signiﬁcant increase in intracellular ROS, mitochondrial de-
polarization, and reduced mitochondrial viability. Concur-
rent treatment with < 1nM SS-31 signiﬁcantly decreased in-
tracellular ROS, increased mitochondrial potential, and pre-
vented tBHP-induced apoptosis.
The remarkable potency of SS-31 can be explained by its
extensivecellularuptakeandselectivepartitioningintomito-
chondria. Intracellular concentrations of [3H]SS-31 were 6-
fold higher than extracellular concentrations. Studies using
isolated mitochondria revealed that [3H]SS-31 was concen-
trated approximately 5000-fold in the mitochondrial pellet.
By concentrating in the inner mitochondrial membrane, SS-
31 became localized to the site of ROS production, and pro-
tected against mitochondrial oxidative damage and against
further ROS production. SS-31 represents a novel platform
for mitochondria-targeted antioxidants with broad thera-
peutic potential [105].
CONCLUSIONS
Recent advances in molecular, cellular, and animal model
studies have revealed that mitochondria are the major source
of free radical generation and of oxidative damage in ag-
ing and age-related neurodegenerative diseases. It is possi-
ble that age-related mitochondrial abnormalities and oxida-
tivedamagearemajorcontributingfactorsforlate-onsetAD.
To stop or delay the progression of late-onset AD, and also
to reduce disease symptoms, several therapeutic strategies
have been developed, including anti-inﬂammatory, antioxi-
dant, and antiamyloid approaches. Among these, mitochon-
drial antioxidant therapy reduces AD pathology more than
any other approach. However, until recently, a major limita-
tion in developing antioxidant therapies for AD patients has
been the inability to enhance antioxidant levels in mitochon-
dria. There has been a breakthrough in the mitochondrial
targeting of antioxidants. Mitochondrially targeted antiox-
idants have been developed, which preferentially enter the
mitochondria—at several hundred-fold more than they en-
ter natural antioxidants—where they rapidly neutralize free
radicals and decrease mitochondrial toxicity. However, fur-
ther research is needed to determine whether these mito-
chondriallytargetedantioxidantscanbeusedinmousemod-
els of aging and in age-related neurodegenerative diseases
such as Alzheimer’s, Parkinson’s, and Huntington’s.
ABBREVIATIONS
3NP 3-nitropropionic acid
ABAD alcohol dehydrogenase
Aβ amyloid beta
ACh acetylcholine
AD Alzheimer’s disease
ApoE apolipoprotein E
APP amyloid precursor protein
ATP adenosine triphosphate
BChE butylcholinesterase
ChAT choline acetyltransferase
ETC electron transport chain
H2O2 hydrogen peroxide
MCAT mitochondrial catalase
MitoVitE mitochondrially targeted vitamin E
MitoQ mitochondrially targeted ubiquinone
MitoPBN mitochondrially targeted α-phenyl-N-tert-butyl
nitrone
N2a neuroblastoma
NCAT nuclear catalase
NFT neuroﬁbrillary tangle
O
•−
2 superoxide anion
PBN α-phenyl-N-tert-butyl nitrone
ROS reactive oxygen species
SOD superoxide dismutase
tBHP t-butylhydroperoxide
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